All data are based on the daily closing price as of March 28, 2025
a

ALTEOGEN

196170.KQ
240.25 USD
-0.03
-0.01%

Overview

Last close
240.25 usd
Market cap
12.80B usd
52 week high
318.01 usd
52 week low
40.51 usd
Target price
384.39 usd

Valuation

P/E
N/A
Forward P/E
N/A
Price/Sales
182.6512
Price/Book Value
68.6659
Enterprise Value
12.66B usd
EV/Revenue
180.9645
EV/EBITDA
463.7344

Key financials

Revenue TTM
69.98M usd
Gross Profit TTM
43.57M usd
EBITDA TTM
19.22M usd
Earnings per Share
N/A usd
Dividend
N/A usd
Total assets
277.49M usd
Net debt
N/A usd

About

ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology; and ALT-LS2, a SC (subcutaneous) formulation of trastuzuamb for the treatment of breast and gastric cancer. The company has a strategic alliance with Kissei Pharmaceutical for the development of ALT-L9, a biosimilar of Eylea (Aflibercept) which is currently under Phase 1 trial; and Cristalia for the development of ALT-L2, a biosimilar of Herceptin (Trastuzumab), a monoclonal antibody for the treatment of breast cancer, which is in the Phase II clinical trial. ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.
  • Symbol
    196170.KQ
  • Exchange
    KQ
  • Isin
    KR7196170005
  • Country
    South Korea
  • Sector
    Healthcare
  • Industry
    Biotechnology
  • CEO
    Dr. Soon-Jae Park Ph.D.
  • Headquarter
    Daejeon
  • Web site
    https://www.alteogen.com
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top